国家神经系统疾病临床医学研究中心数据管理与共享系统

Data Management And Sharing System of China National Clinical Research Center for Neurological Diseases

ATRX, IDH1-R132H and Ki-67 immunohistochemistry as a classification scheme for astrocytic tumors.

第一作者:Jinquan Cai

通讯作者:Yongli Li, Tao Jiang,Chuanlu Jiang

ATRX; IDH-R132H; Ki-67; astrocytic tumors; progres

基本信息

  • 负责人:Jinquan Cai
  • 数据来源: OTHERS
  • 论文编号:OTHERS20190466
  • 发表时间:2016-09-06

2016-09-06

已发表文章

发表杂志:Oncoscience

发表类型: Research Article

影响因子(IF): NA

PMID: 27713914 Pubmed原文链接 全文下载

主要研究背景及目的

方法

In this study, we detected ATRX, IDH1-R132H and Ki-67 by immunohistochemistry and observed the association of IDH1-R132H with ATRX and Ki-67 expression.

结论

The new model demonstrated a remarkable separation of the progression interval in the three molecular subgroups and the distribution of patients' age in the A1-A2-A3 model was also significant different. This model will aid predicting the overall survival and progressive time of astrocytic tumors' patients.

主要结果

There was a strong association between ATRX loss and IDH1-R132H (p<0.0001). However, Ki-67 high expression restricted in the tumors with IDH1-R132H negative (p=0.0129). Patients with IDH1-R132H positive or ATRX loss astrocytic tumors had a longer progressive- free survival (p<0.0001, p=0.0044, respectively). High Ki-67 expression was associated with shorter PFS in patients with astrocytic tumors (p=0.002). Then we characterized three prognostic subgroups of astrocytic tumors (referred to as A1, A2 and A3).